logo-loader
viewFSD Pharma

FSD Pharma adds Dr Lary Kaiser and three other medical professionals to scientific advisory board

The new appointments come as the medical cannabis company advances its efforts to pursue development of CBD-based therapies to replace widely used opioid painkillers in treatment programs

doctor kaiser
Dr Kaiser was named one of the 50 most influential health executives in 2019

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) is boosting its scientific advisory board with the appointment of four new medical professionals, including renowned physcian Dr Larry Kaiser as chairman of the committee.

The new appointments come as the medical cannabis company advances its efforts to pursue development of CBD-based therapies to replace widely used opioid painkillers in treatment programs.

Dr Kaiser is the Dean of the Lewis Katz School of Medicine at Temple University and serves as the CEO of the Philadelphia-based university’s health system. He was named one of the “50 Most Influential Health Executives” by Modern Healthcare magazine earlier in 2019.

READ: FSD Pharma finalizes US$17.5M acquisition of R&D pharma company Prismic Pharmaceuticals

Kaiser’s long career in medicine began after his graduation from Tulane University and included a residency stint at the University of Toronto. He also served on the faculty at the world-renowned Memorial Sloan-Kettering Cancer Center, the Washington University School of Medicine and the University of Pennsylvania.

"I am delighted to Chair the Scientific Advisory Board of FSD Pharma, which is represented by a diverse group of remarkable researchers and clinicians in the medicinal cannabis space,” Kaiser said in a statement.

“FSD Pharma's strategic intent to advance R&D of FDA approved clinical trials of synthetic & biosynthetic cannabinoids compounds is very compelling and I am looking forward to assisting the company meet its objectives.”

In addition to Kaiser’s appointment as chair, Toronto-based FSD added Dr Adam Friedman, Dr Ken Mackie and Dr Sara Jane Ward, three leading cannabis researchers and scientists, to its scientific advisory board.

 Raza Bokhari, FSD’s CEO said: “I am delighted to welcome Drs. Kaiser, Friedman, Mackie and Ward to the FSD Pharma Scientific Advisory Board, where they join some of the country’s most distinguished thought leaders in the clinical development of medicinal cannabis therapeutics.

“The depth and breadth of knowledge of this team is without equal and will be invaluable as our Biosciences Division advances under the leadership of Dr. Edward Brennan. This Division is pursuing R&D of novel cannabinoid-based and opioid-sparing therapies targeting the human endo-cannabinoid system.”

The new appointments bring FSD’s scientific board membership to nine professionals. Kaiser is replacing outgoing chairman Dr Charles Pollack, who has been placed on a leave of absence, according to FSD.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: FSD Pharma

Price: 6.25 CAD

CSE:HUGE
Market: CSE
Market Cap: $48.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FSD Pharma CEO updates corporate moves, progress at hydroponic cannabis facility

FSD Pharma Inc (CSE:HUGE) (OTCQB: FSDDF) interim CEO Dr. Raza Bokhari updates Proactive Investors on the cannabis company's partners, management, and recent achievements. Bokhari says FSD is on track to transform its 25,000 sq. ft facility in Cobourg, Canada into the world’s largest...

on 19/2/19

2 min read